Literature DB >> 19838105

Morbidity and mortality outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution: towards a new perspective of this treatment.

Terence C Chua1, Akshat Saxena, J F Schellekens, Winston Liauw, Tristan D Yan, Sal Fransi, Jing Zhao, David L Morris.   

Abstract

INTRODUCTION: Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) is a treatment option for peritoneal surface malignancy. Despite the survival benefits, this treatment was previously associated with a high morbidity and mortality rates and the perception of the poor perioperative outcomes associated with this regimen remains. The aim of this study was to report the perioperative outcomes of CRS and PIC from a single institution to review factors that are associated with a poor perioperative outcome.
METHODS: The clinical- and treatment-related data of 243 consecutive procedures performed were prospectively collected and retrospectively reviewed. Adverse events were rated according to the National Cancer Institute's Common Toxicity Criteria (grade I-V). Univariate and multivariate analyses were performed to identify significant clinical and treatment-related factors for a poor perioperative outcome (grades III/IV/V morbidity).
RESULTS: The perioperative mortality rate was 3%. The rate of severe morbidity was 43%. Multivariate analysis demonstrated that left upper quadrant peritonectomy (P < 0.001) and small bowel resection (P < 0.01) were factors that predicted for a poor perioperative outcome.
CONCLUSIONS: The morbidity and mortality rates of CRS and PIC are within an acceptable range for a major gastrointestinal surgery which is performed with a curative intent. Patient selection is important in ensuring that suitable patients receive this treatment. A new perspective of this treatment needs to be sought.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19838105     DOI: 10.1097/SLA.0b013e3181b5ae43

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  21 in total

1.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.

Authors:  Ayman Zaki Azzam; Zyad Adil Alyahya; Ahmed Abbas Al Wusaibie; Tarek Mahmoud Amin
Journal:  Indian J Gastroenterol       Date:  2017-11-29

2.  Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: The University of Arizona early experience.

Authors:  Ioannis T Konstantinidis; Christine Young; Vassiliki L Tsikitis; Ellyn Lee; Tun Jie; Evan S Ong
Journal:  World J Gastrointest Surg       Date:  2012-06-27

3.  Does Intraoperative Systematic Bacterial Sampling During Complete Cytoreductive Surgery (CRS) with Hyperthermic Intraoperative Peritoneal Chemotherapy (HIPEC) Influence Postoperative Treatment? A New Predictive Factor for Postoperative Abdominal Infectious Complications.

Authors:  Marie Dazza; Lilian Schwarz; Julien Coget; Noelle Frebourg; Gregory Wood; Emmanuel Huet; Valérie Bridoux; Benoit Veber; Jean-Jacques Tuech
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

4.  Survival outcomes in patients aged 75 years and over with peritoneal colorectal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): multicenter study of the Spanish Group of Peritoneal Cancer Surgery (GECOP).

Authors:  P A Cascales-Campos; V López-López; J Torres-Melero; A Arjona; F C Muñoz-Casares; P Barrios; R Morales; F Pereira; P Bretcha-Boix; L González-Bayón; S González-Moreno; J Gil
Journal:  Clin Transl Oncol       Date:  2019-05-02       Impact factor: 3.405

5.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignant disease.

Authors:  Wenceslao Vásquez Jiménez; Luis González Bayón; José Luis García-Sabrido; Santiago González Moreno
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

6.  Inhibition of LPS-mediated TLR4 activation abrogates gastric adenocarcinoma-associated peritoneal metastasis.

Authors:  Veena Sangwan; Luai Al-Marzouki; Sanjima Pal; Vivian Stavrakos; Malak Alzahrani; Dorothy Antonatos; Yehonatan Nevo; Sophie Camilleri-Broët; Roni Rayes; France Bourdeau; Betty Giannias; Nicholas Bertos; Swneke Bailey; Simon Rousseau; Jonathan Cools-Lartigue; Jonathan D Spicer; Lorenzo Ferri
Journal:  Clin Exp Metastasis       Date:  2021-11-12       Impact factor: 5.150

7.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.

Authors:  Parissa Tabrizian; Brian Shrager; Ghalib Jibara; Ming-Jim Yang; Anya Romanoff; Spiros Hiotis; Umut Sarpel; Daniel M Labow
Journal:  J Gastrointest Surg       Date:  2014-02-28       Impact factor: 3.452

8.  Preliminary Experience and Morbidity Analysis of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) from a Tertiary Cancer Center in India.

Authors:  Naveen Padmanabhan; Barath Raj Kumar; Ansar Pullampara Pookunju; Ayyapan Srinivasan; Vikash Mahajan
Journal:  J Clin Diagn Res       Date:  2015-06-01

9.  Hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: A multicenter propensity score-matched cohort study.

Authors:  Ziying Lei; Jiahong Wang; Zhi Li; Baozhong Li; Jiali Luo; Xuejun Wang; Jin Wang; Mingchen Ba; Hongsheng Tang; Qingjun He; Quanxing Liao; Xiansheng Yang; Tianpei Guan; Han Liang; Shuzhong Cui
Journal:  Chin J Cancer Res       Date:  2020-12-31       Impact factor: 5.087

10.  Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan.

Authors:  Akiyoshi Mizumoto; Emel Canbay; Masamitsu Hirano; Nobuyuki Takao; Takayuki Matsuda; Masumi Ichinose; Yutaka Yonemura
Journal:  Gastroenterol Res Pract       Date:  2012-06-18       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.